

# Program

#### 8:00 am

**Breakfast (L2 Gallery PGCRL)** 

#### 8:30 am

## Welcome and Opening Remarks (L2 Auditorium PGCRL)

Jim Stavropoulos, PhD, FCCMG Clinical Lab Director, Genetics Hospital for Sick Children and University of Toronto

#### 8:40 am

#### **Observations on Clinical Genomics From the Sidelines**

Steve Scherer, PhD

Director, McLaughlin Centre and The Centre for Applied Genomics Hospital for Sick Children and University of Toronto

#### 9:00 am

## Prenatal Diagnosis in Ontario – Past, Present and Future

David Chitayat, MD, FABMG, FACMG, FCCMG, FRCPC Head, The Prenatal Diagnosis and Medical Genetics Program Department of Obstetrics and Gynecology Mount Sinai Hospital and The Hospital for Sick Children University of Toronto

#### 9:40 am

### Prenatal Array CGH in CHU Ste-Justine: 5 Years of Experience.

Frédérique Tihy, PhD, FCCMG Cytogénéticienne, Service de génétique médicale CHU Ste-Justine, Montréal

# 10:10 am Coffee Break

#### 10:30 am

# Predicting the Challenges of Prenatal Microarray from the Postnatal Experience.

Abdul Noor, PhD CCMG Cytogenetics Fellow, Hospital for Sick Children

#### 10:50 am

## Born in the USA: The American Approach to Prenatal Arrays.

Marsha Speevak, PhD, FCCMG, FACMG
Genetics Laboratory Director, Trillium Health Partners, CVH
University of Toronto

#### 11:10 am

# Challenges of Consent in the Changing Prenatal Genetic Landscape

Kerry W. Bowman, PhD Clinical Ethicist, Mount Sinai Hospital

#### 11:30 am

## Prenatal Genetics Going Array.

Hana Sroka, MSC, CCGC, CGC Department of Obstetrics and Gynecology, Mount Sinai Hospital

#### 12:00 pm

Lunch (L2 Gallery PGCRL)

#### 12:45 pm

### Prenatal Array in the UK; Achieving a Consensus?

Bronwyn Kerr, MBBS, FRACP, FRCPCH, FRCP Consultant Clinical Geneticist, Associate Medical Director, Manchester Centre for Genomic Medicine

### 1:25 pm

## Prenatal Microarray: the Belgian Consensus

Bettina Blaumeiser, MD, PhD Gynaecologist/Clinical Geneticist Centrum Medische Genetica UZA/UA

## 2:05 pm

# Break-Out Session – Group Discussions and Consensus Buildina

3:35 pm Coffee break

## 3:55 pm

Group Presentations (4 x 15 min each)

## 5:00 pm

**Closing Remarks** 

#### 5:10 pm

Wine and Cheese Reception (PGCRL 13<sup>th</sup> Floor Atrium)

## **Break-Out Session Topics**

## Group 1. Availability and Access to Testing

How do we ensure access to testing is medically appropriate and equitable in a public healthcare system? How should screening and detection algorithms change as NIPT and microarray become available? What is the role of G-banding?

### **Group 2. Counselling and Education**

How do we overcome the challenges associated with education and consenting? What are the key elements of the consenting process? Should a signed consent be mandatory for invasive genomic testing? Should parents have a choice for return of results?

## **Group 3. Genomic Technologies and Reporting of Results**

Microarray resolution – same as for postnatal or lower resolution?
Under what circumstances do we report VOUS from prenatal arrays?
Considerations for susceptibility loci associated with neuropsychiatric disorders.

How do we deal with medically actionable incidental findings, carrier status, and X-linked mutations identified in a female fetus?

#### Group 4. Considerations for the future

How will advances in genomic diagnostics impact screening and invasive diagnostics in 3 to 5 years?

# **Organizing Committee**

David Chitayat,
Hospital for Sick Children, Mount Sinai Hospital, University of Toronto

Elena Kolomietz,

Mount Sinai Hospital and University Of Toronto

Hin C. Lee, University of Toronto McLaughlin Centre

Stephen Scherer,
Hospital for Sick Children and University of Toronto

Marsha Speevak,
Trillium Health Partners and University of Toronto

Hana Sroka, Mount Sinai Hospital

Jim Stavropoulos, Hospital for Sick Children and University of Toronto

